Inbec可治疗什么病症呢？

In 2018, GlaxoSmithKline (GSK) announced that its joint venture ViiV Healthcare's single-pill compound preparation Suimeikai (()), which is based on the new generation integrase inhibitor Tevicai (dolutegravir) and is used to treat HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. Existing research shows that one year (48 weeks) after treatment with Inbec, 93% of HIV-infected patients turned negative.

The ingredients of Inbec are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Three drugs are used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir.

Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle).

Inbec is suitable for teenagers and adults over 12 years old and weighing no less than 40kg. For adults and teenagers, the recommended dosage of Inbec is one tablet each time, once a day. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax because Trimax is a fixed-dose tablet and the dose cannot be reduced.

Inbec is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines.

On January 22, 2018, Suimeike () was launched in China to treat people infected with human immunodeficiency virus (HIV). Among HIV-infected patients, regardless of the patient's race, before starting treatment with abacavir-containing products, they should be screened for carrying the HLA-B5701 allele. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.